Lv1
40 积分 2023-11-07 加入
XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53 -mutated myeloid malignancies
20天前
已完结
Treatment for relapsed acute promyelocytic leukemia
1个月前
已完结
Acute Promyelocytic Leukemia
1个月前
已完结
The earliest thymic progenitors for T cells possess myeloid lineage potential
3个月前
已完结
Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series
3个月前
已完结
Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial
4个月前
已完结
Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes
8个月前
已完结
皖公网安备34019202002308
